Fielder Capital Group LLC Buys Shares of 390 Eli Lilly and Company (NYSE:LLY)

Fielder Capital Group LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 390 shares of the company’s stock, valued at approximately $227,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Lipe & Dalton purchased a new position in Eli Lilly and Company in the 4th quarter valued at about $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the third quarter valued at approximately $27,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $36,000. Family CFO Inc acquired a new stake in Eli Lilly and Company during the third quarter worth approximately $40,000. Finally, O Brien Wealth Partners LLC grew its stake in Eli Lilly and Company by 70.5% in the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after acquiring an additional 31 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LLY shares. Morgan Stanley raised their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Bank of America lifted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a report on Wednesday, February 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Finally, Barclays increased their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Stock Up 4.3 %

Shares of NYSE LLY traded up $31.77 during trading on Monday, reaching $766.74. 3,396,224 shares of the stock were exchanged, compared to its average volume of 3,090,840. The company has a market capitalization of $728.72 billion, a price-to-earnings ratio of 112.92, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37. The business’s 50-day moving average price is $760.96 and its 200 day moving average price is $673.52. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.62 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.68%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.